A recent study update on Terns Pharmaceuticals’ targeted leukemia drug, TERN-701, found that it successfully achieved a 64% molecular response rate in advanced-stage patients with chronic myeloid leukemia. This positive result has investors optimistic about the treatment’s potential as a successor to a commercial blockbuster from Novartis.
Source: https://www.statnews.com/2025/12/08/terns-leukemia-drug-ash-results-tern-701